» Articles » PMID: 33599178

Hypothetical Emergence of Poliovirus in 2020: Part 2. Exploration of the Potential Role of Vaccines in Control and Eradication

Overview
Date 2021 Feb 18
PMID 33599178
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The emergence of human pathogens with pandemic potential motivates rapid vaccine development. We explore the role of vaccines in control and eradication of a novel emerging pathogen.

Methods: We hypothetically simulate emergence of a novel wild poliovirus (nWPV) in 2020 assuming an immunologically naïve population. Assuming different nonpharmaceutical interventions (NPIs), we explore the impacts of vaccines resembling serotype-specific oral poliovirus vaccine (OPV), novel OPV (nOPV), or inactivated poliovirus vaccine (IPV).

Results: Vaccines most effectively change the trajectory of an emerging disease when disseminated early, rapidly, and widely in the background of ongoing strict NPIs, unless the NPIs successfully eradicate the emerging pathogen before it establishes endemic transmission. Without strict NPIs, vaccines primarily reduce the burden of disease in the remaining susceptible individuals and in new birth cohorts. Live virus vaccines that effectively compete with the nWPVs can reduce disease burdens more than other vaccines. When relaxation of existing NPIs occurs at the time of vaccine introduction, nWPV transmission can counterintuitively increase in the short term.

Conclusions: Vaccines can increase the probability of disease eradication in the context of strict NPIs. However, successful eradication will depend on specific immunization strategies used and a global commitment to eradication.

Citing Articles

Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).

Badizadegan N, Wassilak S, Estivariz C, Wiesen E, Burns C, Bolu O Pathogens. 2024; 13(9).

PMID: 39338995 PMC: 11435063. DOI: 10.3390/pathogens13090804.


Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.

Thompson K, Badizadegan K Pathogens. 2024; 13(6).

PMID: 38921733 PMC: 11206708. DOI: 10.3390/pathogens13060435.


Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.

Thompson K, Kalkowska D, Kidd S, Burns C, Badizadegan K Vaccine. 2024; 42(4):819-827.

PMID: 38218668 PMC: 10947589. DOI: 10.1016/j.vaccine.2023.12.081.


Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.

Badizadegan K, Kalkowska D, Thompson K Med Decis Making. 2023; 43(7-8):850-862.

PMID: 37577803 PMC: 10680042. DOI: 10.1177/0272989X231191127.


Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.

Kalkowska D, Wassilak S, Wiesen E, Burns C, Pallansch M, Badizadegan K Risk Anal. 2023; 44(2):366-378.

PMID: 37344934 PMC: 10733544. DOI: 10.1111/risa.14158.